Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Authors Cernes R, Mashavi M, Zimlichman R

Published Date December 2011 Volume 2011:7 Pages 749—759


Published 12 December 2011

Relu Cernes1,2, Margarita Mashavi1,3, Reuven Zimlichman1,3
1The Brunner Institute for Cardiovascular Research, Wolfson Medical Center and Tel Aviv University, Tel Aviv, Israel; 2Department of Nephrology, Wolfson Medical Center, Holon, Israel; 3Department of Medicine, Wolfson Medical Center, Holon, Israel

Abstract: The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.

Keywords: angiotensin receptor blockers, candesartan, candesartan cilexetil, clinical trials, efficacy studies, safety, blood pressure

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells

Khan AA, Paul A, Abbasi S, Prakash S

International Journal of Nanomedicine 2011, 6:1069-1081

Published Date: 24 May 2011

Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi

Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, Rossi M, Stricker RB

Infection and Drug Resistance 2011, 4:97-113

Published Date: 3 May 2011

The use of nanocrystalline cellulose for the binding and controlled release of drugs

John K Jackson, Kevin Letchford, Benjamin Z Wasserman, et al

International Journal of Nanomedicine 2011, 6:321-330

Published Date: 10 February 2011

Management of hypoactive sexual desire disorder in women: current and emerging therapies

Rossella E Nappi, Ellis Martini, Erica Terreno, et al

International Journal of Women's Health 2010, 2:167-175

Published Date: 1 July 2010

In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection

Torben Gjetting, Nicolai Skovbjerg Arildsen, Camilla Laulund, et al

International Journal of Nanomedicine 2010, 5:371-383

Published Date: 25 May 2010

SLN as a topical delivery system for Artemisia arborescens essential oil: In vitro antiviral activity and skin permeation study

Francesco Lai, Chiara Sinico, Alessandro De Logu, Marco Zaru, Rainer H Müller, Anna M Fadda

International Journal of Nanomedicine 2007, 2:419-425

Published Date: 10 October 2007

Occipital lobe infarctions are different

Halvor Naess, Ulrikke Waje-Andreassen, Lars Thomassen

Vascular Health and Risk Management 2007, 3:413-415

Published Date: 4 October 2007

Nanoparticles in modern medicine: State of the art and future challenges

Shashi K Murthy

International Journal of Nanomedicine 2007, 2:129-141

Published Date: 16 August 2007

Zinc tetraaminophthalocyanine-Fe3O4 nanoparticle composite for laccase immobilization

Jun Huang, Cheng Liu, Haiyan Xiao, Juntao Wang, Desheng Jiang

International Journal of Nanomedicine 2007, 2:775-784

Published Date: 28 January 2007